Colibri Enters TAVR Joint Venture With Venus Medtech Focusing On Emerging Markets
Executive Summary
US firm Colibri Heart Valve and China-based Venus Medtech have formed a venture to commercialize two heart valves in China and other emerging markets: a balloon-expandable version created by Colibri and a self-expanding version developed by Venus using tissue processed by Colibri.
You may also be interested in...
China's Venus Persists With Global TAVR Solutions Expansion
Venus Medtech, the Chinese transcatheter aortic valve technology specialist, has made its second international acquisition as it pursues its strategy for global expansion in the TAVR market.
News We’re Watching: FDA Approves Medtronic's Affera, Roche's CGM Moves Closer To Approval, And More
Medtech Insight's News We're Watching covers medtech industry and research news you may have missed. This week, the Advanced Technologies and Treatments for Diabetes (ATTD) conference in Florence, Italy, included new results from studies of Roche's continuous glucose monitor and Medtronic's 780G insulin pump, Medtronic moved closer to earning FDA approval for its Affera ablation mapping and ablation system, and Linus Health expanded its technology for finding signs of cognitive problems in speech data.
New’s We’re Watching: J&J's Varipulse PFA Earns CE Mark; Labs Create Intravascular Robots; And More
Medtech Insight's News We're Watching highlights some recent business and R&D developments you may have missed. This week, Biosense Webster’s Varipulse PFA platform earned a CE mark; Biosense Webster also announced the start the pivotal IDE study of its Laminar left atrial appendage elimination system; the FDA approved Boston Scientific's Agent paclitaxel-coated balloon and cleared Medtronic's OsteoCool 2.0 bone ablation system; three papers in Science Robotics describe magnetically controlled vascular robots that could go places wires and catheters cannot.